Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Nov 15

PMID 30423915

Citations 17

Authors

Francesca Musumeci

Chiara Greco

Giancarlo Grossi

Alessio Molinari

Silvia Schenone

Affiliations

Soon will be listed here.

Abstract

Ponatinib is a third line drug for the treatment of chronic myeloid leukemia patients, especially those that develop the gatekeeper mutation T315I, which is resistant to the first and the second line drugs imatinib, nilotinib, dasatinib and bosutinib. The compound was first identified as a pan Bcr-Abl and Src kinase inhibitor. Further studies have indicated that it is a multitargeted inhibitor that is active on FGFRs, RET, AKT, ERK1/2, KIT, MEKK2 and other kinases. For this reason, the compound has been evaluated on several cancers in which these kinases play important roles, including thyroid, breast, ovary and lung cancer, neuroblastoma, rhabdoid tumours and in myeloproliferative disorders. Ponatinib is also being tested in clinical trials to evaluate its activity in FLT3-ITD acute myelogenous leukemia, head and neck cancers, certain type of lung cancer, gastrointestinal stromal tumours and other malignancies. In this review we report the most recent preclinical and clinical studies on ponatinib in cancers other than CML, with the aim of giving a complete overview of this interesting compound.

Citing Articles

Quality by design-based approach for the development of an analytical method for quantifying ponatinib in rat plasma.

Koo N, Lee E, Kim M, Park M, Lee K, Chae Y Heliyon. 2024; 10(19):e38637.

PMID: 39403541 PMC: 11471595. DOI: 10.1016/j.heliyon.2024.e38637.

Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis.

Krajcsir B, Pocsi M, Fejes Z, Nagy Jr B, Kappelmayer J, Debreceni I Pharmaceutics. 2024; 16(4).

PMID: 38675220 PMC: 11055157. DOI: 10.3390/pharmaceutics16040559.

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia.

Verhagen N, Koenderink J, Blijlevens N, Janssen J, Russel F Pharmaceutics. 2023; 15(11).

PMID: 38004514 PMC: 10675650. DOI: 10.3390/pharmaceutics15112535.

A renaissance for YES in cancer.

Lapouge M, Meloche S Oncogene. 2023; 42(46):3385-3393.

PMID: 37848624 DOI: 10.1038/s41388-023-02860-x.

Current Insights and Progress in the Clinical Management of Head and Neck Cancer.

Amaral M, Faisca P, Ferreira H, Gaspar M, Reis C Cancers (Basel). 2022; 14(24).

PMID: 36551565 PMC: 9776832. DOI: 10.3390/cancers14246079.

References

Jabbour E, Kantarjian H . Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014; 89(5):547-56. DOI: 10.1002/ajh.23691. View

Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Bohmer F, Hochhaus A . Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol. 2012; 157(4):483-92. DOI: 10.1111/j.1365-2141.2012.09085.x. View

Li S, Cheuk A, Shern J, Song Y, Hurd L, Liao H . Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013; 8(10):e76551. PMC: 3790700. DOI: 10.1371/journal.pone.0076551. View

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-9. DOI: 10.1158/1078-0432.CCR-06-1516. View

Whittle S, Patel K, Zhang L, Woodfield S, Du M, Smith V . The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs. 2016; 34(6):685-692. DOI: 10.1007/s10637-016-0387-y. View

Shao W, Li S, Li L, Lin K, Liu X, Wang H . Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun. Protein Cell. 2018; 10(3):161-177. PMC: 6338618. DOI: 10.1007/s13238-018-0533-8. View

Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P . Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012; 26(7):1693-5. DOI: 10.1038/leu.2012.8. View

Chase A, Bryant C, Score J, Cross N . Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica. 2012; 98(1):103-6. PMC: 3533670. DOI: 10.3324/haematol.2012.066407. View

Li H, Wang Y, Chen Z, Lu J, Pan J, Yu Y . Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo. Oncotarget. 2016; 8(4):5874-5884. PMC: 5351597. DOI: 10.18632/oncotarget.11580. View

10.

Greulich H, Pollock P . Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med. 2011; 17(5):283-92. PMC: 3809064. DOI: 10.1016/j.molmed.2011.01.012. View

11.

Lee M, Lee K, Min A, Kim J, Kim S, Jang H . Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. Cancer Res Treat. 2018; 51(2):451-463. PMC: 6473293. DOI: 10.4143/crt.2017.341. View

12.

Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts N . Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2012; 98(2):E364-9. PMC: 3565108. DOI: 10.1210/jc.2012-2703. View

13.

Kim D, Kwak Y, Kim N, Sim T . Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations. Cancer Biol Ther. 2015; 17(1):65-78. PMC: 4847821. DOI: 10.1080/15384047.2015.1108492. View

14.

Gozgit J, Wong M, Wardwell S, Tyner J, Loriaux M, Mohemmad Q . Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011; 10(6):1028-35. PMC: 3236248. DOI: 10.1158/1535-7163.MCT-10-1044. View

15.

Muller M, Cervantes F, Hjorth-Hansen H, Janssen J, Milojkovic D, Rea D . Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017; 120:52-59. DOI: 10.1016/j.critrevonc.2017.10.002. View

16.

Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G . Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010; 163(2):301-8. DOI: 10.1530/EJE-10-0333. View

17.

Roskoski Jr R, Sadeghi-Nejad A . Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacol Res. 2017; 128:1-17. DOI: 10.1016/j.phrs.2017.12.021. View

18.

Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J . Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncol. 2018; 15(3):257-269. DOI: 10.2217/fon-2018-0371. View

19.

Laramy J, Kim M, Gupta S, Parrish K, Zhang S, Bakken K . Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther. 2017; 363(2):136-147. PMC: 5625285. DOI: 10.1124/jpet.117.243477. View

20.

Huang Q, Schneeberger V, Luetteke N, Jin C, Afzal R, Budzevich M . Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther. 2016; 15(10):2521-2529. PMC: 5289739. DOI: 10.1158/1535-7163.MCT-16-0258. View